W
E
N
Add Corlanor® to maximally tolerated doses of beta-blockers and help
give appropriate patients with stable, symptomatic chronic heart failure...
MORE HOME.
For patients with stable, symptomatic chronic HF with LVEF ≤ 35% and in sinus rhythm with resting heart rate ≥ 70 bpm:
Corlanor® significantly reduced the relative risk of hospitalization
for worsening HF or CV death by 18% (4.2% ARR; P < 0.0001)
1, 2
– Composite endpoint result reflected only a reduction in the risk of hospitalization for
worsening HF with no favorable effect on CV death
Indication
Corlanor® (ivabradine) is indicated to reduce the risk of
hospitalization for wo '6V